top of page

Final guideline on core SmPC for human plasma derived and recombinant coagulation factor VIII produc

This guideline describes the information to be included in the Summary of Product Characteristics (SmPC) for human plasma derived and recombinant coagulation factor VIII products, which are indicated for use in the treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency).

Click on this link for more information.

#RegulatoryAffairsHuman #LegislationRegulatoryAffairs

Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page